CVKD logo

Cadrenal Therapeutics Stock Price

Symbol: NasdaqCM:CVKDMarket Cap: US$20.3mCategory: Pharmaceuticals & Biotech

CVKD Share Price Performance

US$8.81
2.74 (45.09%)
US$8.81
2.74 (45.09%)
Price US$8.81

CVKD Community Narratives

There are no narratives available yet.

CVKD Community Fair Values

    Recent CVKD News & Updates

    No updates

    Cadrenal Therapeutics, Inc. Key Details

    US$0

    Revenue

    US$0

    Cost of Revenue

    US$0

    Gross Profit

    US$12.8m

    Other Expenses

    -US$12.8m

    Earnings

    Last Reported Earnings
    Mar 31, 2025
    Next Reporting Earnings
    n/a
    Earnings per share (EPS)
    -6.53
    Gross Margin
    0%
    Net Profit Margin
    0%
    Debt/Equity Ratio
    0%

    Cadrenal Therapeutics, Inc. Competitors

     
     
     
     
     
     
     
     
     
     
     
     

    About CVKD

    Founded
    2022
    Employees
    4
    CEO
    Quang Pham
    WebsiteView website
    www.cadrenal.com

    Cadrenal Therapeutics, Inc. operates as a late-stage biopharmaceutical company focuses on developing therapeutics for rare cardiovascular conditions. The company is developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. It has a collaboration agreement with Abbott Global Enterprises Limited to evaluate the efficacy and safety of Tecarfarin in patients with a left-ventricular assist device. Cadrenal Therapeutics, Inc. was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.

    U.S. Market Performance

    • 7 Days: -1.2%
    • 3 Months: 13.1%
    • 1 Year: 22.8%
    • Year to Date: 7.3%
    Over the last 7 days, the market has dropped 1.2%, driven by a decline of 4.7% in the Consumer Discretionary sector. In contrast to the last week, the market is actually up 23% over the past year. Earnings are forecast to grow by 15% annually. Market details ›
    This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
    Continue reading